


Pre-clinical study of YH34160 for obesity treatment



METABOLIC	Non-clinical
Product Type	Long acting Fc-Fusion protein
Indication	Obesity
Target	GDF15 receptor agonist
MoA(Mechanism of Action)	Body weight loss via food intake inhibition
Competitiveness	<ul style="list-style-type: none"> • Novel mode of action on body weigh loss • Potent functional activity by enhancing receptor binding • Optimal PK profile suitable for once-weekly dosing in human
Development Stage	Non-clinical
Route of Administration	Subcutaneous injection